[wpml_language_selector_widget]
[wpml_language_selector_widget]

Reading and Resources

Websites

Articles and Further Reading

  1. Bassetti C, Aldrich M. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997;120:1423-1435.
  2. Billiard M, Merle C, Carlander B, et al. Idiopathic hypersomnia. Psychiatr Clin Neurosci. 1998;52:125-129.
  3. Blachier M, Dauvilliers Y, Jaussent I, et al. Excessive daytime sleepiness and vascular events: the Three City Study. Ann Neurol. 2012;71(5):661-667.
  4. Bock J, Covassin N, Somers V. Excessive daytime sleepiness: an emerging marker of cardiovascular risk. Heart. 2022;108(22):1761-1766.
  5. Heo YA. Calcium, magnesium, potassium and sodium oxybates in sleep disorders: a profile of its use. CNS Drugs. 2022;36(5):541-549.
  6. Johns M. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14: 540-545.
  7. Junnarkar G, Allphin C, Profant J, Steininger TL, Chen C, Zomorodi K, Skowronski R, Black J. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17(2):109-119.
  8. Monderer R, Ahmed IM, Thorpy M. Evaluation of the sleepy patient: differential diagnosis. Sleep Med Clin. 2017;12:301-312.
  9. Morse AM, Dauvilliers Y, Arnulf I, et al. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. J Clin Sleep Med. 2023;19(10):1811-1822.
  10. Neikrug A, Crawford M, Ong J. Behavioral sleep medicine services for hypersomnia disorders: a survey study. Behav Sleep Med. 2016:1-14.
  11. Pascoe M, Bena J, Foldvary-Schaefer N. Effects of pharmacotherapy treatment on patient-reported outcomes in a narcolepsy and idiopathic hypersomnia cohort. J Clin Sleep Med. 2019;15(12):1799-1806. 
  12. Ramm M, Boentert M, Lojewsky N, et al. Disease-specific attention impairment in disorders of chronic excessive daytime sleepiness. Sleep Med. 2019;53:133-140. 
  13. Saad R, et al. Characteristics of adults newly diagnosed with idiopathic hypersomnia in the United States. Sleep Epidemiol. 2023;3:100059.
  14. Saad R, Lillaney P, Profant D, et al. PH231 Cardiovascular burden of patients diagnosed with idiopathic hypersomnia: Real-world idiopathic hypersomnia total health model (CV-RHYTHM). Value Health. 2023;26(6_suppl):S205. doi:10.1016/j.jval.2023.03.2577
  15. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387-1394.
  16. Schneider LD, Stevens J, Husain AM, et al. Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the Real-World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:89-101.
  17. Stevens J, Schneider LD, Husain AM, et al. Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the Real-World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:593-606.
  18. Thorpy M, Krahn L, Ruoff C, et al. Clinical considerations in the treatment of idiopathic hypersomnia. Sleep Med. 2024;119:488-498.
  19. Trotti L. Idiopathic hypersomnia. Sleep Med Clin. 2017;12:331-344.
  20. Trotti LM, Ong JC, Plante DT, et al. Disease symptomatology and response to treatment in people with idiopathic hypersomnia: initial data from the Hypersomnia Foundation registry. Sleep Med. 2020;75:343-349.
  21. Vernet C, Arnulf I. Narcolepsy with long sleep time: a specific entity? Sleep. 2009;32:1229-1235.

Understanding IH

Assessment

IH and Cardiovascular Risk

Cognitive Impact

Treating and Managing IH

Patient Support Strategies

Reading and Resources

This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Jazz Pharmaceuticals.
Copyright © 2024 | Med Learning Group | All Rights Reserved | Website by Divigner

Pin It on Pinterest

Scroll to Top

You are now leaving the THRIVE site

The THRIVE Neuroscience Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the THRIVE educational initiative and MLG is not responsible for its content.

I acknowledge
Go Back

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers